Objective: Comparing the effects of Vaccinium arctostaphylos fruit extract on cardiometabolic indices with placebo in hypertensive obese patients. Study design: randomized, double-blind, placebo-controlled, two group parallel design, single-center, phase 2 of clinical trial. Study population: Hypertensive obese patients. Sample size: 100 patients. Inclusion criteria: Iranian male and female hypertensive obese outpatients; patients aged 30 to 80 years; patients with body mass index between 25 kilograms per square meter and 35 kilograms per square meter; patients with systolic blood pressures between 14 and 16 mmHg; patients with diastolic blood pressures between 8 and 10 mmHg; patients taking synthetic antihypertensive drugs with 2 different mechanisms. Exclusion criteria: Patients taking other drugs effective on the blood glucose and lipid levels and body weight; patients with cardiac, renal, hepatic, hematological diseases, hypothyroidism, tachycardia, vertigo and seizure; patients with a history of gallstones or gall bladder surgery; pregnant women; women planning pregnancy; breast-feeding women. Interventions: Vaccinium arctostaphylos fruit extract is administered at the dose of one 400 mg capsule every 8 hours to a group of 50 patients for 3 months and one placebo capsule is administered every 8 hours to another group of 50 patients for 3 months. Before intervention and 3 months after intervention, the primary and secondary outcome variables are evaluated. Primary outcome variables: Blood levels of glycosylated hemoglobin and LDL-C, amounts of systolic and diastolic blood pressures, body mass index, waist circumference. Secondary outcome variables: Blood levels of fasting glucose, total cholesterol, triglyceride, HDL-C, creatinine, SGOT and SGPT.